Meeting
2014 ASCO Annual Meeting
Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL).
Authors
Bartomeu Massuti
Hospital General de Alicante, Alicante, Spain
Bartomeu Massuti , Rosario García Campelo , Delvys Rodriguez Abreu , Jordi Remon , Margarita Majem , Elisa Galvez , Jose Antonio Ortega , Francisco Aparisi , Noemi Reguart , María Ángeles Sala , Dolores Isla , Maria Sanchez Ronco , Ana Verdu , Miguel Angel Molina-Vila , Clara Mayo-de las Casas , Eva Pereira , Rosana Cajal , Maria Carmen Gonzalez-Arenas , Enric Carcereny , Rafael Rosell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT=1513174
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8127)
DOI
10.1200/jco.2014.32.15_suppl.tps8127
Abstract #
TPS8127
Poster Bd #
303B
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).
First Author: Rosario Garcia Campelo
Poster
2018 ASCO Annual Meeting
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).
First Author: Rosario Garcia Campelo
First Author: Chee Lee
First Author: Karen L. Reckamp